Heron Therapeutics (NASDAQ:HRTX) perks up 3% premarket in response to its announcement that it has initiated its Phase 2 clinical trial, GUARDS-1, evaluating Cinvanti (aprepitant) in early hospitalized adult COVID-19 patients.
The company posted the study in ClinicalTrials.gov on Tuesday.
https://seekingalpha.com/news/3591823-heron-launches-mid-stage-study-of-aprepitant-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.